Filters

Clear all

Expert Opinion

Plain Language Summary

Expert Review

Text Availability

Abstract

26

Full text

22

Free full text

10

Publication Types

Journal Article

26

Research Support, Non-U.S. Gov't

18

Randomized Controlled Trial

8

Review

7

Multicenter Study

6

Research Support, N.I.H., Extramural

5

Clinical Trial, Phase III

3

Comparative Study

2

Clinical Trial

2

Research Support, N.I.H., Intramural

1

Research Support, U.S. Gov't, Non-P.H.S.

1

Comment

1

Clinical Trial, Phase I

1

Editorial

1

Publication Year

From

To

Quick links

Individual year

2022

1

2021

1

2017

1

2016

2

2015

2

2012

2

2011

2

2010

1

2008

4

2007

4

2006

4

2005

1

2004

1

2002

1

Sort by:

selected

Print page

Email selected articles

Favourite selected articles

Create a NED Search Alert for this search

Save this search

Advanced Search

Run an advanced search

Results for
""Protein Kinase C beta""[mesh_terms]

27 Results

Searching titles within these results

Treatment of diabetic retinopathy with protein kinase C subtype Beta inhibitor.

Gabriele E Lang

Developments in ophthalmology 2007;39():157-165

Clinical safety of the selective PKC-beta inhibitor, ruboxistaurin.

Janet B McGill, George L King, Paul H Berg, Karen L Price, Keri A Kles, Edward J Bastyr, David L Hyslop

Expert opinion on drug safety 2007;5(6):835-45

Differential recruitment of PKC isoforms in HeLa cells during redox stress.

Alessandro Rimessi, Rosario Rizzuto, Paolo Pinton

Cell stress & chaperones 2008;12(4):291-8

Medical management of diabetic retinopathy.

A K Sjølie, F Møller

Diabetic medicine : a journal of the British Diabetic Association 2004;21(7):666-72

Therapeutic hypothermia augments the restorative effects of PKC-β and Nox2 inhibition on an in vitro model of human blood-brain barrier.

Ulvi Bayraktutan, Zoe McCarthy, Mansour Alwjwaj, Rais Reskiawan A Kadir

Metabolic brain disease 2022;36(7):1817-1832

Potential new medical therapies for diabetic retinopathy: protein kinase C inhibitors.

Robert N Frank

American journal of ophthalmology 2002;133(5):693-8

Ruboxistaurin for diabetic retinopathy.

David A Antonetti, Thomas W Gardner

Ophthalmology 2006;113(12):2135-6

Melatonin Pathway and Atenolol-Related Glucose Dysregulation: Is There a Correlation?

C W McDonough, Y Gong, S W Chang, T Y Langaee, R M Cooper-DeHoff, J A Johnson, S T Turner, A B Chapman, J G Gums, A L Beitelshees, N Nasiri Kenari

Clinical and translational science 2016;9(2):114-22

Update on treatments of diabetic macular edema.

Xiao-lu Yang, Kun Liu, Xun Xu

Chinese medical journal 2010;122(22):2784-90

Phosphorylation of meprin β controls its cell surface abundance and subsequently diminishes ectodomain shedding.

Kira Bickenbach, Christoph Becker-Pauly, Claus Pietrzik, Andreas Tholey, Tomas Koudelka, Fred Armbrust

FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2021;35(7):e21677

DIABETIC MACULAR EDEMA.

Ovidiu Musat, Ana Maria Boureanu, Madalina Zamfir, Oana Toma, Andreea Gheorghe, Mahdi Labib, Corina Cernat

Romanian journal of ophthalmology 2016;59(3):133-6

Protein kinase C beta and delta isoenzymes mediate cholesterol accumulation in PMA-activated macrophages.

Hong-Tao Ma, Wan-Wan Lin, Bin Zhao, Wen-Tung Wu, Wei Huang, Yifu Li, Nancy L Jones, Howard S Kruth

Biochemical and biophysical research communications 2006;349(1):214-20

Effect of ruboxistaurin (RBX) On visual acuity decline over a 6-year period with cessation and reinstitution of therapy: results of an open-label extension of the Protein Kinase C Diabetic Retinopathy Study 2 (PKC-DRS2).

Matthew J Sheetz, Lloyd Paul Aiello, Nazila Shahri, Matthew D Davis, Keri A Kles, Ronald P Danis

Retina (Philadelphia, Pa.) 2011;31(6):1053-9

The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial.

Diabetes 2005;54(7):2188-97

A phase 1 and pharmacokinetic study of enzastaurin in pediatric patients with refractory primary central nervous system tumors: a pediatric brain tumor consortium study.

Susan M Blaney, James M Boyett, Larry Kun, Maryam Fouladi, Richard Gilbertson, Anuradha Banerjee, Stewart Goldman, Jack Su, Murali Chintagumpala, Cynthia Wetmore, Mehmet Kocak, Lindsay B Kilburn, Rodney L Decker

Neuro-oncology 2015;17(2):303-11

Results: 1 – 15 / 27

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

Sponsor

Sponsor

Sponsor

Sponsor

Sponsor

Sponsor

Sponsor

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.